Sukhdeep S. Sahi MBBS , Oscar Garcia Valencia MD , Jie Na MS , Adley Lemke PharmD , Dustin Duffy MS , Byron Smith MS , Pavel Navratil MD , Pooja Budhiraja MBBS , Tayyab S. Diwan MD , Naim Issa MD , Mark D. Stegall MD , Aleksandar Denic MD, PhD , Ahmed A. Abdelrheem MB, ChB , Hani M. Wadei MD , Walter D. Park , Pankaj Shah MD , Yogish C. Kudva MD , Aleksandra Kukla MD
{"title":"肾移植后胰高血糖素样肽-1受体激动剂的益处。","authors":"Sukhdeep S. Sahi MBBS , Oscar Garcia Valencia MD , Jie Na MS , Adley Lemke PharmD , Dustin Duffy MS , Byron Smith MS , Pavel Navratil MD , Pooja Budhiraja MBBS , Tayyab S. Diwan MD , Naim Issa MD , Mark D. Stegall MD , Aleksandar Denic MD, PhD , Ahmed A. Abdelrheem MB, ChB , Hani M. Wadei MD , Walter D. Park , Pankaj Shah MD , Yogish C. Kudva MD , Aleksandra Kukla MD","doi":"10.1016/j.eprac.2025.02.020","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in kidney transplant (KT) recipients have not been adequately studied.</div></div><div><h3>Methods</h3><div>We retrospectively examined the effects of GLP-1 RA on mortality, kidney outcomes and metabolic parameters in KT recipients with type 2 diabetes mellitus (T2DM) treated versus not treated with GLP-1 RA. A reference group of KT recipients not treated with GLP-1 RA was used for comparison. Data were analyzed using analysis of variance, χ2 tests, and generalized estimating equation models. GLP-1 RA was used as a time-dependent model in Cox regression modeling. For survival analysis, the final model fitting was stratified by race-ethnicity.</div></div><div><h3>Results</h3><div>Seventy-seven KT recipients with T2DM were treated with GLP-1 RA for at least 12 months. Reference group included 2094 patients not on GLP-1 RA. The mean (SD) age at transplant was 57.9 (9.5) and 60.8 (9.5) years for the treatment and reference groups, respectively. Median follow-up time from the index date for mortality was 1.5 (IQR 0.99, 2.4) in the treatment and 5.8 (IQR 3.4, 9.1) years in the reference group. GLP-1 RA use was associated with improved survival (<em>P</em> = .049), decreased urine albumin to creatinine ratio (net reduction of 10.62 mg/g per year, <em>P</em> = .003), slower estimated glomerular filtration rate decline (1.04 vs 1.56 mL/min/1.73 m<sup>2</sup> per year, <em>P</em> = .04), and lower troponin levels.</div></div><div><h3>Conclusions</h3><div>GLP-1 RA in KT recipients with T2DM was associated with reduced mortality, and improved kidney function compared to the reference group. Larger, prospective studies are needed to fully evaluate the risks and benefits of GLP-1 RA therapy in KT recipients.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 6","pages":"Pages 798-804"},"PeriodicalIF":3.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Benefits of Glucagon-like Peptide-1 Receptor Agonists After Kidney Transplantation\",\"authors\":\"Sukhdeep S. Sahi MBBS , Oscar Garcia Valencia MD , Jie Na MS , Adley Lemke PharmD , Dustin Duffy MS , Byron Smith MS , Pavel Navratil MD , Pooja Budhiraja MBBS , Tayyab S. Diwan MD , Naim Issa MD , Mark D. Stegall MD , Aleksandar Denic MD, PhD , Ahmed A. Abdelrheem MB, ChB , Hani M. Wadei MD , Walter D. Park , Pankaj Shah MD , Yogish C. Kudva MD , Aleksandra Kukla MD\",\"doi\":\"10.1016/j.eprac.2025.02.020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in kidney transplant (KT) recipients have not been adequately studied.</div></div><div><h3>Methods</h3><div>We retrospectively examined the effects of GLP-1 RA on mortality, kidney outcomes and metabolic parameters in KT recipients with type 2 diabetes mellitus (T2DM) treated versus not treated with GLP-1 RA. A reference group of KT recipients not treated with GLP-1 RA was used for comparison. Data were analyzed using analysis of variance, χ2 tests, and generalized estimating equation models. GLP-1 RA was used as a time-dependent model in Cox regression modeling. For survival analysis, the final model fitting was stratified by race-ethnicity.</div></div><div><h3>Results</h3><div>Seventy-seven KT recipients with T2DM were treated with GLP-1 RA for at least 12 months. Reference group included 2094 patients not on GLP-1 RA. The mean (SD) age at transplant was 57.9 (9.5) and 60.8 (9.5) years for the treatment and reference groups, respectively. Median follow-up time from the index date for mortality was 1.5 (IQR 0.99, 2.4) in the treatment and 5.8 (IQR 3.4, 9.1) years in the reference group. GLP-1 RA use was associated with improved survival (<em>P</em> = .049), decreased urine albumin to creatinine ratio (net reduction of 10.62 mg/g per year, <em>P</em> = .003), slower estimated glomerular filtration rate decline (1.04 vs 1.56 mL/min/1.73 m<sup>2</sup> per year, <em>P</em> = .04), and lower troponin levels.</div></div><div><h3>Conclusions</h3><div>GLP-1 RA in KT recipients with T2DM was associated with reduced mortality, and improved kidney function compared to the reference group. Larger, prospective studies are needed to fully evaluate the risks and benefits of GLP-1 RA therapy in KT recipients.</div></div>\",\"PeriodicalId\":11682,\"journal\":{\"name\":\"Endocrine Practice\",\"volume\":\"31 6\",\"pages\":\"Pages 798-804\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrine Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1530891X25000680\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1530891X25000680","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Benefits of Glucagon-like Peptide-1 Receptor Agonists After Kidney Transplantation
Objective
Benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in kidney transplant (KT) recipients have not been adequately studied.
Methods
We retrospectively examined the effects of GLP-1 RA on mortality, kidney outcomes and metabolic parameters in KT recipients with type 2 diabetes mellitus (T2DM) treated versus not treated with GLP-1 RA. A reference group of KT recipients not treated with GLP-1 RA was used for comparison. Data were analyzed using analysis of variance, χ2 tests, and generalized estimating equation models. GLP-1 RA was used as a time-dependent model in Cox regression modeling. For survival analysis, the final model fitting was stratified by race-ethnicity.
Results
Seventy-seven KT recipients with T2DM were treated with GLP-1 RA for at least 12 months. Reference group included 2094 patients not on GLP-1 RA. The mean (SD) age at transplant was 57.9 (9.5) and 60.8 (9.5) years for the treatment and reference groups, respectively. Median follow-up time from the index date for mortality was 1.5 (IQR 0.99, 2.4) in the treatment and 5.8 (IQR 3.4, 9.1) years in the reference group. GLP-1 RA use was associated with improved survival (P = .049), decreased urine albumin to creatinine ratio (net reduction of 10.62 mg/g per year, P = .003), slower estimated glomerular filtration rate decline (1.04 vs 1.56 mL/min/1.73 m2 per year, P = .04), and lower troponin levels.
Conclusions
GLP-1 RA in KT recipients with T2DM was associated with reduced mortality, and improved kidney function compared to the reference group. Larger, prospective studies are needed to fully evaluate the risks and benefits of GLP-1 RA therapy in KT recipients.
期刊介绍:
Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE). The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.